Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8696410 | 0.78 | ATAD2 (0.38) | LMNAALDH1A1POLBL3MBTL1SMN1; SMN2 | |
| SCHEMBL19235507 | 0.76 | BRD4 (0.36) | LMNAALDH1A1POLBL3MBTL1TSHR | |
| SCHEMBL14491564 | 0.76 | BRD4 (0.36) | LMNAALDH1A1POLBL3MBTL1TSHR | |
| SCHEMBL11869254 | 0.76 | BRPF1 (0.35) | LMNAALDH1A1POLBL3MBTL1SMN1; SMN2 | |
| SCHEMBL3806347 | 0.76 | FEN1 (0.38) | LMNAALDH1A1POLBSMN1; SMN2HSD17B10 | |
| SCHEMBL23029099 | 0.75 | BRD4 (0.35) | LMNAALDH1A1POLBL3MBTL1 | |
| SCHEMBL9972888 | 0.75 | ALDH1A1 (0.40) | LMNAALDH1A1POLBL3MBTL1SMN1; SMN2 | |
| SCHEMBL12766925 | 0.75 | LMNA (0.40) | LMNAALDH1A1POLBL3MBTL1TSHR | |
| SCHEMBL17254245 | 0.75 | ERN1 (0.37) | LMNAALDH1A1POLBTSHRSMN1; SMN2 | |
| SCHEMBL18937487 | 0.75 | BRD4 (0.35) | LMNAALDH1A1POLBL3MBTL1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230027396-A1 | EXCIPIENT COMPOUNDS FOR BIOPOLYMER FORMULATIONS | COMERA LIFE SCIENCES, INC. | 2023-01-26 | — | — | US | claimed |
| EP-4065166-A1 | EXCIPIENT COMPOUNDS FOR BIOPOLYMER FORMULATIONS | Comera Life Sciences, Inc. (US) | 2022-10-05 | — | — | EP | claimed |
| CN-109799313-B | Nitrogen-doped carbon material nano enzyme based on nucleic acid base or derivative thereof, and preparation method and application thereof | 南京大学 | 2021-07-27 | — | — | CN | claimed |
| WO-2021108427-A1 | EXCIPIENT COMPOUNDS FOR BIOPOLYMER FORMULATIONS | REFORM BIOLOGICS, LLC (US) | 2021-06-03 | — | — | WO | claimed |
| JP-55111420-A | — | — | None | — | — | JP | disclosed |
| WO-2024071439-A1 | FUSED RING COMPOUND AND PHARMACEUTICAL CONTAINING SAME | 科研製薬株式会社 | 2024-04-04 | — | — | WO | disclosed |
| WO-2023242662-A2 | POLYMERIC TANDEM DYES WITH SPACING LINKER GROUPS | Sony Group Corporation (JP) | 2023-12-21 | — | — | WO | disclosed |
| WO-2023242661-A2 | POLYMERIC TANDEM DYES WITH SPACING LINKER GROUPS | Sony Group Corporation (JP) | 2023-12-21 | — | — | WO | disclosed |
| US-20230348524-A1 | TECHNOLOGIES FOR OLIGONUCLEOTIDE PREPARATION | WAVE LIFE SCIENCES LTD. (SG) | 2023-11-02 | — | — | US | disclosed |
| US-11771738-B2 | Endoparasitic depsipeptides | ZOETIS SERVICES LLC (US) | 2023-10-03 | — | — | US | disclosed |
| US-20230250127-A1 | MODIFIED mRNA 5'-CAP ANALOGS | Nanjing GeneLeap Biotechnology Co., Ltd. (CN) | 2023-08-10 | — | — | US | disclosed |
| WO-2023150592-A2 | N3-SUBSTITUTED URACIL COMPOUNDS AS TRPA1 INHIBITORS | D.E. SHAW RESEARCH, LLC (US) | 2023-08-10 | — | — | WO | disclosed |
| US-20070025933-A1 | Photoprotector and/or photoimmunoprotector compositions of the skin and their uses | INDUSTRIAL FARMACEUTICA CANTABRIA, S.A. (ES) | 2007-02-01 | — | — | US | disclosed |
| WO-2005094773-A1 | PHOTOPROTECTIVE AND/OR PHOTOIMMUNOPROTECTIVE COMPOSITIONS FOR THE SKIN AND USES THEREOF | INDUSTRIAL FARMACEUTICA CANTABRIA, S.A. (ES) | 2005-10-13 | — | — | WO | disclosed |
| US-5874477-A | ADMINISTERING AN AMINOTETRALIN, A PHENYL DIOXIN, A AN ERGOLINE, AN INDOLE DERIVATIVE OR AN ALKYLPIPERIDINE, PRECURSORS OF WHICH ARE FRUIT PEELINGS; DISPLACEMENT OF LIGANDS ON SUBTYPE 5HT1A OR 5HT2/5HT1C; REDUCE SYMPTOMS | THE UNIVERSITY OF HAWAII (US) | 1999-02-23 | — | — | US | disclosed |
| WO-1996004898-A1 | A METHOD OF TREATMENT FOR MALARIA | MCCONNELL BRUCE (US) | 1996-02-22 | — | — | WO | disclosed |
| JP-S55111420-A | ANTITUMORIGENIC AGENT | ONO PHARMACEUT CO LTD | 1980-08-28 | — | — | JP | disclosed |
| US-4210651-A | Thiaprostaglandins | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1980-07-01 | — | — | US | disclosed |
| US-4171429-A | Pyrimidine to pyrimidine transformation process | RESEARCH CORPORATION (US) | 1979-10-16 | — | — | US | disclosed |
| US-4080458-A | HYPOTENSIVE AGENTS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DT) | 1978-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070025933-A1 | Photoprotector and/or photoimmunoprotector compositions of the skin and their uses | ME1, ME2, SI | LMNA 3635/4885ALDH1A1 2765/4885POLB 350/4885 |
| US-20230250127-A1 | MODIFIED mRNA 5'-CAP ANALOGS | RNGTT, RNMT, NSUN2 | LMNA 1771/4885ALDH1A1 3421/4885POLB 534/4885 |
| US-11771738-B2 | Endoparasitic depsipeptides | VIP, PREP, VIPR1 | LMNA 2449/4885ALDH1A1 2109/4885POLB 4515/4885 |
| US-20230348524-A1 | TECHNOLOGIES FOR OLIGONUCLEOTIDE PREPARATION | POLRMT, DCLRE1B, RNGTT | LMNA 2479/4885ALDH1A1 3318/4885POLB 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.